Description
Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program’s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias. Abhimanyu Garg, MBBS, MD Professor of Internal Medicine UT Southwestern Medical Center Department of Internal Medicine 5323 Harry Hines Blvd Dallas, TX 75390 TEL 214-648-2895 Chapter 1. Lipoprotein Physiology Chapter 2. Epidemiology of Blood Lipids and Lipoproteins Chapter 3. Lipoprotein(a) Chapter 4. Lipoproteins and Cardiovascular Disease Risk Chapter 5. Detection and Treatment of Children and Adolescents with Dyslipidemia Chapter 6. Type 2 Diabetes Mellitus and Dyslipidemia Chapter 7. Type 1 Diabetes Mellitus and Dyslipidemia Chapter 8. Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome Chapter 9. Dyslipidemia in HIV-infected Patients Chapter 10. Monogenic Hypercholesterolemia Chapter 11. Primary Hypertriglyceridemia Chapter 12. Genetic Disorders of HDL Metabolism Chapter 13. Sitosterolemia and Other Rare Sterol Disorders Chapter 14. Genetic Abetalipoproteinemia & Hypobetalipoproteinemia Chapter 15. Drug-induced Dyslipidemia Chapter 16. Lipodystrophies and Dyslipidemias Chapter 17. Novel Genes for Dyslipidemias: Genome-Wide Association Studies Chapter 18. Perspectives on Cholesterol Guidelines Chapter 19. Nutrition and Coronary Heart Disease Prevention Chapter 20. Phytosterol Therapy Chapter 21. N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease Chapter 22. Polyphenols for Cholesterol Management Chapter 23 – Dietary Supplements for Cholesterol Management Chapter 24. Statins: Risk-Benefits and Role in Treating Dyslipidemias Chapter 25. Fibrates: Risk-Benefits and Role in Treating Dyslipidemias Chapter 26. Niacin: Risk-Benefits and Role in Treating Dyslipidemias Chapter 27. Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias Chapter 28. Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias Chapter 29. Low Density Lipoprotein (LDL) Apheresis Chapter 30. Novel Lipid Lowering Agents
